Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Matsumura, Y.
Right arrow Articles by Takahashi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumura, Y.
Right arrow Articles by Takahashi, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:517-525, 2004
© 2004 European Society for Medical Oncology

Original Paper

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

Received 6 August 2003; revised 3 October 2003; accepted 10 November 2003

Background:

MCC-465 is an immunoliposome-encapsulated doxorubicin (DXR). The liposome is tagged with polyethylene glycol (PEG) and the F(ab')2 fragment of human monoclonal antibody GAH, which positively reacts to >90% of cancerous stomach tissues, but negatively to all normal tissues. In preclinical studies, MCC-465 showed superior cytotoxic activity against several human stomach cancer cells compared with DXR or DXR-incorporated PEG liposomes. The main purpose of this trial was to define the maximum tolerated dose (MTD), dose limiting toxicity (DLT), recommended phase II dose and pharmacokinetics (PK) of MCC-465.

Patients and methods:

Patients with metastatic or recurrent stomach cancer were eligible for entry. The initial dose was 6.5 mg/m2. MCC-465 was administered as a 1-h infusion every 3 weeks and the treatment continued for up to six cycles.

Results:

Twenty-three patients received a total of 62 cycles at the 6.5–45.5 mg/m2 dose level. DLTs were myelosuppression and appetite loss at the 45.5 mg/m2 dose level. Other toxicities were mild. Neither palmar–plantar erythrodysesthesia nor cardiotoxicity was observed. Acute reactions related to infusion were observed commonly in 16 patients over the entire dose range. While no antitumor response was observed, stable disease (SD) was observed in 10 out of 18 evaluable patients. The pharmacokinetic study showed a similar AUC and Cmax to Doxil®.

Conclusion:

MCC-465 was well tolerated. The recommended dose for a phase II study of MCC-465, for a 3-week schedule, is considered to be 32.5 mg/m2 in an equivalent amount of DXR.

Y. Matsumura1,*, M. Gotoh2, K. Muro2, Y. Yamada2, K. Shirao2, Y. Shimada2, M. Okuwa3, S. Matsumoto3, Y. Miyata3, H. Ohkura3, K. Chin4, S. Baba4, T. Yamao4, A. Kannami5, Y. Takamatsu5, K. Ito5 and K. Takahashi5

1 Investigative Treatment Division, National Cancer Center Research Institute East, 2 National Cancer Center Hospital, Tokyo; 3 Ibaraki Prefectural Central Hospital, Ibaraki; 4 Cancer Institute Hospital, Tokyo; 5 Mitsubishi Pharma Corporation, Tokyo, Japan

Key words: doxorubicin, drug delivery system, GAH, immunoliposome, MCC-465, pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
X. Wang, L. Yang, Z. Chen, and D. M. Shin
Application of Nanotechnology in Cancer Therapy and Imaging
CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. R. Blumen, K. Cheng, M. E. Ramos-Nino, D. J. Taatjes, D. J. Weiss, C. C. Landry, and B. T. Mossman
Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells
Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 333 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Tuffin, E. Waelti, J. Huwyler, C. Hammer, and H.-P. Marti
Immunoliposome Targeting to Mesangial Cells: A Promising Strategy for Specific Drug Delivery to the Kidney
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3295 - 3305.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.